



emcdda

Minutes

Meeting	54th meeting of the Scientific Committee
Date	18 November 2021
Venue	EMCDDA (meeting room 107) and VC
Present	See participants list (Annex 1)

1. Adoption of the agenda

The Chair, Catherine Comiskey, welcomed the Scientific Committee members, the spokesperson of the Reitox network (Brian Galvin) and the EMCDDA staff present at the 54th Scientific Committee meeting. Anne Line Bretteville-Jensen, Fabrizio Faggiano, Henri Bergeron and Krzysztof Krajewski, as well as the Heads of the Scientific Units (Jane Mounteney and Roumen Sedefov) attended the meeting online. Laura Amato was excused.

The Chair informed the meeting that it was being recorded and addressed the participants in the room regarding the use of masks there.

The agenda (Annex 2) was unanimously adopted.

2. Feedback from the chair relevant meetings and documents

The Chair provided feedback on the meetings she attended as representative of the Scientific Committee since the last Scientific Committee meeting in May: 1) the 63rd Management Board meeting in June and 2) the Annual Dialogue on Research (ADR) in October, where she presented the *Contribution from the EMCDDA Scientific Committee* (Annex 3). She also provided updates on the status of the *Formal opinion of the Scientific Committee on the SPD 2022-24* (Annex 4) and the Scientific Committee position paper *Extending EMCDDA's monitoring and reporting framework* (Annex 5). Members of the Scientific Committee still wanting to provide comments on the position paper *Extending EMCDDA's monitoring and reporting framework*, before the document is presented to the Management Board, at their upcoming meeting 16-17 December, by the Chair, should do so as soon as possible.

3. Welcome by the Director and relevant meetings and documents

The EMCDDA Director, Alexis Goosdeel, joined the meeting and welcomed all participants. The Director started by giving an update on the EMCDDA budget and the possible revision of the EMCDDA's mandate. He also thanked the Scientific Committee for drafting the position paper *Extending EMCDDA's monitoring and reporting framework*.

The Director then shared the state of play of the implementation of the new business model of the EMCDDA (Annex 6) and received congratulations and feedback from the members, mostly highlighting the importance of keeping the scientific dimension of the work at the core of the new business model and of an adequate innovation framework.

He ended his intervention by congratulating Fernando Rodriguez de Fonseca on the occasion of 15 years of his membership to the Scientific Committee. The Director and the Chair offered Dr Rodriguez de Fonseca a medal to commemorate this occasion.

4. EMCDDA Futures exercise

The Scientific Director (Paul Griffiths) updated the Scientific Committee on the EMCDDA Futures exercise (Annex 7). He also emphasised the high interest in this topic shown by several stakeholders, including EU-ANSA (EU Agencies Network on Scientific Advice), which has set up a working group around Futures, currently led by the EMCDDA. Member States are also interested and organising initiatives at national level. The Reitox representative, Brian Galvin, informed the committee that such an exercise would be taking place in Ireland, the following week, under the framework of the National Drugs Forum meeting. A possible way forward in this area may be using a futures approach to identify knowledge gaps and research priorities. This could be relevant to the yearly contribution of the Scientific Committee at the HDG's Annual Dialogue on research. The EMCDDA will keep the Scientific Committee informed.

5. Products and outputs 2021

Rosemary Martin de Sousa, Head of the Communication Unit, updated the Scientific Committee members on the recent and upcoming EMCDDA publications and outputs (Annex 8), with a special focus on the online miniguides, that are digitally fully available and allow for quick updates on the website. She also presented the work of the EMCDDA Editorial Board and informed that the EMCDDA is piloting an automatic approach to translation, together with two Reitox national focal points.

6. Follow-up points

6.1. Lisbon Addictions 2022

Maria Moreira gave feedback on the ongoing preparations for the Lisbon Addictions 2022 conference. She reminded that the call for abstracts has been launched and the registrations are open. She informed the committee that Lisbon Addictions 2022 will have fewer parallel tracks than the 2017 and 2019 editions, which will result in a lower number of oral presentations being accepted. Further details on the review process will be shared with the Scientific Committee early in 2022.

7. Any other business (AOB)

The following dates have been selected for the 2022 Scientific Committee meetings: 55th meeting – 20 to 22 April 2022; 56th meeting – 12 to 14 October 2022.

With no other business to discuss, the Chair closed the meeting.

Annexes

Annex 1 – List of participants

Annex 2 – Agenda

Annex 3 – Contribution from the EMCDDA Scientific Committee: Annual Dialogue on Research: Recommendations of the Scientific Committee

Annex 4 – Formal Opinion of the Scientific Committee on the SPD 2022-24

Annex 5 – Scientific Committee position paper *Extending EMCDDA's monitoring and reporting framework*

Annex 6 – Presentation on the New business model (Alexis Goosdeel)

Annex 7 – Presentation on the EMCDDA Futures exercise (Paul Griffiths)

Annex 8 – Presentation 'Update on publications and outputs' (Rosemary Martin de Sousa)